卡瑞利珠单抗在晚期原发性肝癌患者中的临床效果及安全性分析

Clinical Efficacy and Safety of Carrelizumab in Patients with Advanced Primary Liver Cancer

目的观察卡瑞利珠单抗在晚期原发性肝癌患者中的临床效果及安全性分析。方法将在我院(2019年7月-2021年7月)收治以晚期原发性肝癌为诊断的患者总计60例,以随机数字表法进行分组每组各30例患者,选取其中1组30例患者接受索拉非尼治疗为对照组,另1组30例患者则接受卡瑞利珠单抗治疗为研究组。比较两组患者在接受治疗前、后的肿瘤标志物水平、生存质量评分,并统计治疗效果与不良反应发生的情况。结果两组患者在接受治疗前、后的肿瘤标志物水平相比,差异(P>0.05)无统计学意义。而治疗后的两组肿瘤标志物水平较治疗前明显地下降,且研究组明显低于对照组,差异(P<0.05)有统计学意义。两组患者在接受治疗前生存质量EORTCQLQ-C30评分相比,差异(P>0.05)无统计学意义。而治疗后的两组生存质量EORTCQLQ-C30评分较治疗前明显地升高,且研究组明显高于对照组,差异(P<0.05)有统计学意义。在治疗后研究组患者的治疗客观有效率与疾病控制率均高于对照组,而并发症发生率则低于对照组,差异(P<0.05)有统计学意义。结论在晚期原发性肝癌患者中,以卡瑞利珠单抗治疗,可较为明显地降低患者血清肿瘤标志物水平,改善患者治疗后的生存质量,降低了治疗后并发症的发生,提升治疗的客观有效率与疾病控制率,效果较为理想,值得临床推广。

Objective To observe the clinical effect and safety of rilizumab in patients with advanced primary liver cancer.Methods A total of 60 patients with advanced primary liver cancer diagnosed in our hospital(from July 2019 to July 2021)were divided into groups by random number table,with 30 patients in each group.30 patients in one group were treated with renvatinib as the control group and 30 patients in the other group were treated with rilizumab as the study group.The levels of tumor markers and quality of life scores of the two groups before and after treatment were compared,and the treatment effects and adverse reactions were counted.Results There was no significant difference in the levels of tumor markers between the two groups before and after treatment(P>0.05).The levels of tumor markers in the two groups after treatment were significantly lower than those before treatment,and the study group was significantly lower than that in the control group(P<0.05).There was no significant difference between the two groups in eortcqlq-c30 score of quality of life before treatment(P>0.05).The eortcqlq-c30 score of quality of life in the two groups after treatment was significantly higher than that before treatment,and the study group was significantly higher than that in the control group(P<0.05).After treatment,the objective effective rate and disease control rate of the study group were higher than those of the control group,while the incidence of complications was lower than that of the control group(P<0.05).Conclusion In patients with advanced primary liver cancer,treatment with ruilizumab can significantly reduce the level of serum tumor markers,improve the quality of life of patients after treatment,reduce the incidence of complications after treatment,and improve the objective effective rate and disease control rate of treatment.The effect is ideal and worthy of clinical promotion.